Eurizon Capital SGR S.p.A. Makes New Investment in Kenvue Inc. $KVUE

Eurizon Capital SGR S.p.A. acquired a new position in Kenvue Inc. (NYSE:KVUE) during the fourth quarter, HoldingsChannel reports. The fund acquired 993,448 shares of the company’s stock, valued at approximately $17,138,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of KVUE. Arrowstreet Capital Limited Partnership acquired a new position in Kenvue in the second quarter worth $6,528,000. Jump Financial LLC boosted its stake in Kenvue by 210.6% in the second quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock worth $1,147,000 after purchasing an additional 37,170 shares in the last quarter. AXA S.A. boosted its stake in Kenvue by 21.1% in the second quarter. AXA S.A. now owns 48,892 shares of the company’s stock worth $1,023,000 after purchasing an additional 8,524 shares in the last quarter. NewEdge Advisors LLC boosted its stake in Kenvue by 219.1% in the second quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock worth $2,040,000 after purchasing an additional 66,930 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in Kenvue by 0.6% in the second quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock worth $39,217,000 after purchasing an additional 10,885 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Up 0.0%

Shares of KVUE opened at $17.29 on Monday. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $23.90. The firm has a market capitalization of $33.19 billion, a PE ratio of 20.34, a price-to-earnings-growth ratio of 1.31 and a beta of 0.54. The stock’s fifty day simple moving average is $17.40 and its 200-day simple moving average is $17.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. During the same quarter in the prior year, the firm posted $0.24 earnings per share. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. As a group, research analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th were paid a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a dividend yield of 4.8%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue’s dividend payout ratio is 97.65%.

Insider Activity

In other news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.59% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Argus raised Kenvue to a “hold” rating in a research note on Friday, March 6th. Barclays reduced their price objective on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 14th. UBS Group reduced their price objective on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Canaccord Genuity Group boosted their price objective on Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Finally, Weiss Ratings lowered Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.